Energy Deficiency, ATG4B Nuclear Translocation, and DNA Repa
2026-04-13
Energy Deficiency-Induced ATG4B Nuclear Translocation Impairs DNA Repair in AML
Study Background and Research Question
Cellular energy homeostasis and genomic stability are fundamental to normal cell function, with their disruption implicated in cancer and aging. While the influence of metabolism on DNA repair has been recognized—affecting chromatin modification, nucleotide synthesis, and oxidative stress—specific mechanisms linking energy deficiency to DNA repair pathways remain elusive. Acute myeloid leukemia (AML), characterized by high metabolic demand and genomic instability, presents an ideal context to investigate these links. The present study addresses the question: How does energy deficiency mechanistically disrupt DNA repair in AML cells, and what are the consequences for disease progression? [source_type: paper][source_link: https://doi.org/10.1002/advs.202509838]Key Innovation from the Reference Study
The central innovation of this work lies in identifying the nuclear translocation of ATG4B (an autophagy-related cysteine protease) as a critical mediator of energy deficiency-induced DNA repair defects. The study reveals that, under energy stress, ATG4B enters the nucleus and directly interacts with PRMT1, a protein arginine methyltransferase. This interaction inhibits PRMT1’s ability to methylate MRE11, a core component of the MRN complex central to double-strand break repair. The resulting impairment of DNA repair mechanisms enhances genomic instability and promotes AML progression. This mechanistic insight provides a new axis—energy metabolism-autophagy-DNA repair—connecting metabolic stress to leukemogenesis [source_type: paper][source_link: https://doi.org/10.1002/advs.202509838].Methods and Experimental Design Insights
The authors employed a multi-layered experimental approach, including:- Cell Culture Models: Human AML cell lines and primary patient-derived AML cells were subjected to energy deficiency via glucose deprivation and pharmacological inhibitors.
- Mouse Models: MLLT3-KMT2A-driven AML mouse models and patient-derived xenografts (PDX) were used to validate findings in vivo.
- Subcellular Fractionation & Immunofluorescence: To track ATG4B localization, the study used cell fractionation and confocal microscopy, confirming nuclear translocation under energy stress.
- Protein Interaction Assays: Co-immunoprecipitation demonstrated direct ATG4B–PRMT1 binding.
- DNA Repair & Genomic Instability Assays: γ-H2AX foci quantification, comet assays, and mutation burden analysis measured DNA damage and repair efficiency.
- Functional Outcomes: Cell proliferation, apoptosis, and survival were monitored in vitro and in animal models.
Core Findings and Why They Matter
- Energy Deficiency Triggers ATG4B Nuclear Translocation: Under nutrient stress, ATG4B accumulates in the nucleus, a phenomenon not observed under normal conditions.
- ATG4B Inhibits PRMT1-Mediated MRE11 Methylation: Nuclear ATG4B binds PRMT1, preventing it from methylating MRE11, which is essential for effective DNA double-strand break repair [source_type: paper][source_link: https://doi.org/10.1002/advs.202509838].
- Genomic Instability and AML Progression: This disruption leads to increased DNA damage, higher mutation rates, and accelerated leukemia progression in both patient-derived cells and mouse models.
- Therapeutic Implication: ATG4B Inhibition: Pharmacological or genetic inhibition of ATG4B restored PRMT1 activity, enhanced DNA repair, reduced cell proliferation, and improved survival in AML models.
Comparison with Existing Internal Articles
Recent internal articles such as "Tioconazole: Mechanistic Insights and Metabolic Interplay" and "Tioconazole: Mechanistic Insights and Emerging Roles in AML" have explored the relationship between antifungal medication mechanisms—specifically azole antifungal agents like Tioconazole—and their impact on ergosterol biosynthesis and metabolic-genomic crosstalk. While these articles primarily focus on fungal models, they highlight similar themes of metabolic interference affecting core cellular processes, such as membrane synthesis and genomic stability. The present AML study extends this metabolic-genomic perspective from fungal infection models to oncology, but with a distinct molecular focus (ATG4B–PRMT1–MRE11 axis versus fungal cytochrome P450 inhibition) [source_type: workflow_recommendation][source_link: https://bmx-in-1.com/index.php?g=Wap&m=Article&a=detail&id=12863].Why this cross-domain matters, maturity, and limitations
The analogy between antifungal azoles’ impact on ergosterol biosynthesis (and thus, membrane stability and resistance mechanisms) and the study’s findings in AML demonstrates how metabolic disruption can undermine essential cellular repair systems. However, direct translation of antifungal metabolic models to cancer requires caution, as the molecular targets and cellular contexts differ. The current evidence supports metabolic-genomic interplay as a conceptual bridge but does not yet validate antifungal agents for cancer use [source_type: workflow_recommendation][source_link: https://supra-sieve-gpg.com/index.php?g=Wap&m=Article&a=detail&id=235].Limitations and Transferability
Despite its rigorous experimental design, the study has several limitations:- Cancer-Type Specificity: The findings are specific to AML models, and generalizability to other cancer types or non-malignant cells remains to be established.
- Therapeutic Translation: While ATG4B inhibition shows promise in preclinical models, clinical efficacy and safety are untested.
- Metabolic Context: The role of other metabolic stresses, beyond glucose deprivation, was not fully explored.
- Complexity of DNA Repair Pathways: The focus on PRMT1 and MRE11, while significant, does not account for the broader DNA repair network.
Protocol Parameters
- in vitro DNA repair assay | γ-H2AX foci per nucleus | validated in AML cells | quantifies DNA damage for assessing repair efficiency under metabolic stress | paper
- Energy deprivation protocol | 2–4 mM glucose, 24–48 h | AML cell lines | models metabolic stress relevant to study findings | paper
- ATG4B inhibitor concentration | 1–10 μM (compound-dependent) | in vitro DNA repair enhancement | dose range shown to restore PRMT1 activity and DNA repair | paper
- Mutation burden assay | Whole-exome sequencing, mutation frequency | AML PDX models | measures genomic instability in response to interventions | paper
- Positive control for antifungal agent cytotoxicity | Tioconazole, 2–25 μM | fungal infection model | established concentration range for in vitro antifungal assays | workflow_recommendation